Skip to main content
. 2017 Aug 22;243(2):193–207. doi: 10.1002/path.4939

Figure 6.

PATH-4939-FIG-0006-c

SOX11, an embryonic mammary epithelial marker, predicts poor clinical outcome in breast cancer patients and is expressed in preinvasive breast lesions. (A) Disease‐free survival (DSS) curves for 1032 breast cancer patients with lymph node‐negative disease and with low and high SOX11 expression from analysis of microarray data from the METABRIC dataset. Expression data were stratified into quartiles based on SOX11 expression, and the lowest expression quartile (Q1) was treated as the baseline for the subsequent pairwise comparisons with the remaining quartiles. The statistical significance of pairwise comparisons was assessed with the Wald test. (B) Overall survival (OS) curves for 1032 breast cancer patients with lymph node‐negative disease and with low and high SOX11 expression from analysis of microarray data from the METABRIC dataset. Expression data were stratified into quartiles based on SOX11 expression, and the lowest expression quartile (Q1) was treated as the baseline for the subsequent pairwise comparisons with the remaining quartiles. The statistical significance of pairwise comparisons was assessed with the Wald test. (C and D) Haematoxylin and eosin stain (C) and SOX11 expression (D) in DCIS lesions. Scale bar: 200 μm. HR, hazard ratio.